News & articles

Yelena Ginzburg, MD, Tisch Cancer Institute, Icahn School of Medicine at Mount Sinai Dr. Yelena Ginzburg’s research illustrates how basic research, clinical data, and clinical trial development inform each other in what is often a continuous loop between lab and clinic. Funded by a 2019-2021 MPN Challenge™ award, her work focuses on understanding why iron… Read More »From Lab to Clinic and Back

Our Scientific Advisory Board represents an extraordinary group of MPN thought leaders who contribute a broad range of medical, scientific, and short- and long-term strategic advice to the foundation. We greatly appreciate the commitment by all of the members of this outstanding volunteer board, and welcome five new members. • Radek Skoda, MD, PhD, University… Read More »MPN Leaders Added to Scientific Advisory Board

With a 21-year history of impactful MPN research, we’re proud of where we started, where we are, and most importantly, where we’re headed. Check out our IMPACT@21 story in this new digital report, featuring the voices of leading MPN researchers, clinicians, advocates and people living with ET, PV and MF.

“One of the biggest things that has changed in my life is I’ve had to give things up. I have visual problems (it’s like a blind spot) so I really cut down on my driving. I had to quit cooking because I made so many mistakes. I’ll walk into a room looking for something and… Read More »Voice of the Patient Report Delivered to FDA

Thanks to a robust and growing MPN research community, the 63rd Annual Meeting and Exposition of the American Society of Hematology, ASH-21, was packed with illuminating MPN developments. Summarized here are a few of the exciting ASH 2021 presentations, workshops and posters by global researchers we’re proud to have funded. In addition, some of these… Read More »ASH 2021: Features Multiple MPNRF-Funded Projects 

What’s Next? At the end of a productive meeting, day, or week, I’m always asking myself, “what’s next.” Next on my calendar, next on my list, next on the agenda. Last year, I recognized that to get to what’s next as a foundation, I first had to learn, listen, and prepare. I learned about the… Read More »New Year’s Note from CEO, Kapila Viges

In an article in Targeted Oncology entitled, “The Expanding Role of Interferons in Myeloproliferative Neoplasms,” Dr. Richard Silver, director emeritus of the Silver MPN Center at Weill Cornell Medicine, discussed the importance of our three-year global Interferon Initiative to shed light on key questions such as which patients are likely to benefit from recombinant interferon alpha and why resistance to it may develop over… Read More »Targeted Oncology Highlights Global Interferon Initiative

Earlier this month, we joined our global partners as part of the 6th International MPN Horizons Conference, convening MPN advocates from 33 countries to share the latest research, care standards, and current therapies.  Amongst the rich medical and advocacy content presented, Kapila Viges of MPNRF co-chaired two medical sessions. The first highlighted genetic testing, disease progression,… Read More »Global Research Impacts Patients Around the World

When ruxolitinib (Jakafi®) was approved by the U.S. Food and Drug Administration (FDA) to treat myelofibrosis (MF) ten years ago, it was celebrated as the first treatment specifically for an MPN. Three years later, it was approved to treat polycythemia vera (PV). The landscape for patients is much different now than when ruxolitinib was initially… Read More »The Changing Landscape for Patients

Chicago, IL, November 1, 2021 (Newswire) – In real world usage and in clinical trials, interferon (IFN), in a variety of forms, has shown high rates of hematologic and molecular responses in most patients with polycythemia vera (PV) and essential thrombocythemia (ET), and some patients in the early phase of primary myelofibrosis (PMF), together a… Read More »3-Year Global MPN Interferon Initiative